Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Feb;121(2):588-95.e1.
doi: 10.1016/j.ophtha.2013.09.023. Epub 2013 Dec 12.

Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema

Collaborators, Affiliations
Multicenter Study

Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema

Marc H Levin et al. Ophthalmology. 2014 Feb.

Abstract

Purpose: Among cases of visually significant uveitic macular edema (ME), to estimate the incidence of visual improvement and identify predictive factors.

Design: Retrospective cohort study.

Participants: Eyes with uveitis, seen at 5 academic ocular inflammation centers in the United States, for which ME was documented to be currently present and the principal cause of reduced visual acuity (<20/40).

Methods: Data were obtained by standardized chart review.

Main outcome measures: Decrease of ≥ 0.2 base 10 logarithm of visual acuity decimal fraction-equivalent; risk factors for such visual improvement.

Results: We identified 1510 eyes (of 1077 patients) with visual impairment to a level <20/40 attributed to ME. Most patients were female (67%) and white (76%), and had bilateral uveitis (82%). The estimated 6-month incidence of ≥ 2 lines of visual acuity improvement in affected eyes was 52% (95% confidence interval [CI], 49%-55%). Vision reduced by ME was more likely to improve by 2 lines in eyes initially with poor visual acuity (≤ 20/200; adjusted hazard ratio [HR] 1.5; 95% CI, 1.3-1.7), active uveitis (HR, 1.3; 95% CI, 1.1-1.5), and anterior uveitis as opposed to intermediate (HR, 1.2), posterior (HR, 1.3), or panuveitis (HR, 1.4; overall P = 0.02). During follow-up, reductions in anterior chamber or vitreous cellular activity or in vitreous haze each led to significant improvements in visual outcome (P <0.001 for each). Conversely, snowbanking (HR, 0.7; 95% CI, 0.4-0.99), posterior synechiae (HR, 0.8; 95% CI, 0.6-0.9), and hypotony (HR, 0.2; 95% CI, 0.06-0.5) each were associated with lower incidence of visual improvement with respect to eyes lacking each of these attributes at a given visit.

Conclusions: These results suggest that many, but not all, patients with ME causing low vision in a tertiary care setting will enjoy meaningful visual recovery in response to treatment. Evidence of significant ocular damage from inflammation (posterior synechiae and hypotony) portends a lower incidence of visual recovery. Better control of anterior chamber or vitreous activity is associated with a greater incidence of visual improvement, supporting an aggressive anti-inflammatory treatment approach for ME cases with active inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimate of the incidence of at least two lines improvement in visual acuity among eyes with macular edema causing a reduction of visual acuity to worse than 20/40 (shaded area denotes the 95% confidence interval [CI]).
Figure 2
Figure 2
Kaplan-Meier estimates of the incidence of at least two lines improvement in visual acuity among eyes with macular edmea causing reduction of visual acuity to worse than 20/40, comparing estimates of vision gain among those with baseline activity, inactivity, or slight activity.
Figure 3
Figure 3
Kaplan-Meier estimates of the incidence of at least two lines improvement in visual acuity among eyes with macular edema causing reduction of visual acuity to worse than 20/40, comparing estimates of vision gain among those with anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis.
Figure 4
Figure 4
Influence of the change in uveitis activity over six months on the proportion of eyes with macular edema causing visual acuity to worse than 20/40 that gained at least two lines’ improvement in visual acuity by that time. Error bars denote 95% confidence intervals. p<0.01 comparing degrees of step-wise improvements within each category of uveitis activity. CI = confidence interval

Similar articles

  • Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.
    Tomkins-Netzer O, Lightman SL, Burke AE, Sugar EA, Lim LL, Jaffe GJ, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA; Multicenter Steroid Treatment Trial and Follow-up Study Research Group. Tomkins-Netzer O, et al. Ophthalmology. 2021 May;128(5):719-728. doi: 10.1016/j.ophtha.2020.08.035. Epub 2020 Sep 10. Ophthalmology. 2021. PMID: 32918964 Free PMC article. Clinical Trial.
  • Hypopyon in patients with uveitis.
    Zaidi AA, Ying GS, Daniel E, Gangaputra S, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Zaidi AA, et al. Ophthalmology. 2010 Feb;117(2):366-72. doi: 10.1016/j.ophtha.2009.07.025. Epub 2009 Dec 14. Ophthalmology. 2010. PMID: 20006905 Free PMC article.
  • TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
    Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Sainz de la Maza M, Adán A. Mesquida M, et al. Retina. 2018 Jul;38(7):1361-1370. doi: 10.1097/IAE.0000000000001690. Retina. 2018. PMID: 28520640
  • Macular edema in uveitis.
    Mitkova-Hristova VT, Konareva-Kostianeva MI. Mitkova-Hristova VT, et al. Folia Med (Plovdiv). 2012 Jul-Sep;54(3):14-21. doi: 10.2478/v10153-011-0092-8. Folia Med (Plovdiv). 2012. PMID: 23270202 Review.
  • Epidemiology of Macular Edema in Uveitis.
    Accorinti M, Okada AA, Smith JR, Gilardi M. Accorinti M, et al. Ocul Immunol Inflamm. 2019;27(2):169-180. doi: 10.1080/09273948.2019.1576910. Epub 2019 Mar 1. Ocul Immunol Inflamm. 2019. PMID: 30821631 Review.

Cited by

References

    1. Lardenoye CW, van Kooji B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446–9. - PubMed
    1. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818–24. - PubMed
    1. Yanoff M, Fine BS, Brucker AJ, Eagle RC., Jr Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28(suppl):505–11. - PubMed
    1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6. - PMC - PubMed
    1. Sugar EA, Jabs DA, Altaweel MM, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152:1044–52. - PMC - PubMed

Publication types

MeSH terms

Substances